RJFSA
ADMA icon

Raymond James Financial Services Advisors’s ADMA Biologics ADMA Stock Holding History

Raymond James Financial Services Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$11M Sell
551,887
-31,470
-5% -$489K 0.01% 825
2024
Q2 		$6.52M Buy
583,357
+322,911
+124% +$2.71M 0.01% 1030
2024
Q1 		$1.72M Buy
260,446
+28,196
+12% +$154K ﹤0.01% 1721
2023
Q4 		$1.05M Sell
232,250
-16,227
-7% -$60K ﹤0.01% 1955
2023
Q3 		$890K Buy
248,477
+103,464
+71% +$398K ﹤0.01% 1974
2023
Q2 		$535K Sell
145,013
-12,565
-8% -$46.6K ﹤0.01% 2313
2023
Q1 		$522K Sell
157,578
-5,119
-3% -$17.7K ﹤0.01% 2310
2022
Q4 		$631K Buy
162,697
+15,663
+11% +$48.3K ﹤0.01% 2134
2022
Q3 		$357K Sell
147,034
-93,577
-39% -$225K ﹤0.01% 2474
2022
Q2 		$476K Buy
240,611
+106,186
+79% +$209K ﹤0.01% 2309
2022
Q1 		$246K Sell
134,425
-524
-0.4% -$817 ﹤0.01% 2847
2021
Q4 		$190K Buy
134,949
+25,912
+24% +$34.1K ﹤0.01% 2991
2021
Q3 		$123K Buy
109,037
+34,080
+45% +$47.7K ﹤0.01% 3088
2021
Q2 		$120K Sell
74,957
-453
-0.6% -$797 ﹤0.01% 3116
2021
Q1 		$133K Buy
75,410
+34,408
+84% +$78.8K ﹤0.01% 3004
2020
Q4 		$80K Buy
41,002
+1,202
+3% +$2.53K ﹤0.01% 2876
2020
Q3 		$95K Sell
39,800
-1,925
-5% -$5.28K ﹤0.01% 2700
2020
Q2 		$122K Buy
+41,725
New +$120K ﹤0.01% 2600
2018
Q4 		– Sell
-23,700
Closed -$147K – 2570
2018
Q3 		$147K Buy
23,700
+8,800
+59% +$50.7K ﹤0.01% 2605
2018
Q2 		$67K Buy
+14,900
New +$74.3K ﹤0.01% 2650

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Raymond James Financial Services Advisors's ADMA Position: Q3 2024 in Review

Raymond James Financial Services Advisors reduced its ADMA Biologics (ADMA) stake by 5.4% in Q3 2024, selling an estimated $489K and leaving 551,887 shares worth $11M. The position accounts for 0.01% of the portfolio, ranked #825.

Raymond James Financial Services Advisors first reported a position in ADMA in Q2 2018 and has held it in 20 quarters since. 306 funds tracked by Wall St. Rank hold ADMA as of Q3 2024.

  • Raymond James Financial Services Advisors held 551,887 shares of ADMA Biologics worth $11M as of Q3 2024.
  • Raymond James Financial Services Advisors sold 31,470 ADMA Biologics shares in Q3 2024, an estimated $489K.
  • ADMA Biologics made up 0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #825 holding.
  • Raymond James Financial Services Advisors first reported a position in ADMA Biologics in Q2 2018 and has held it in 20 quarters since.
  • 306 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.